Gaetano Cimino

Dr. Gaetano Cimino

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2024 in Cancers
Verified
Journal Article
Open access
PDF file
SPSara Pierangeli
Sara Pierangeli
SDSerena Donnini
Serena Donnini
VCValerio Ciaurro
Valerio Ciaurro
FMFrancesca Milano
Francesca Milano
VCValeria Cardinali
Valeria Cardinali
MMMaria Paola Martelli
Maria Paola Martelli
How hematopoietic stem and progenitor cell (HSPC) fate decisions are affected by genetic alterations acquired during AML leukemogenesis is poorly understood and mainly explored in animal models. Here, we study isocitrate dehydrogenase (IDH) gene mutations in the human model of HSPC and discuss the available literature on this topic. IDH1/2 mutations occur in ~20% of AML cases, are recognized among the mutations earliest acquired during leukemogenesis, and are targets of specific inhibitors (ivosidenib and enasidenib, respectively). In order to investigate the direct effects of these mutations on HSPCs, we expressed IDH1-R132H or IDH2-R140Q mutants into human CD34+ healthy donor cells via lentiviral transduction and analyzed the colony-forming unit (CFU) ability. CFU ability was dramatically compromised with a complete trilineage block of differentiation. Strikingly, the block was reversed by specific inhibitors, confirming that it was a specific effect induced by the mutants. In line with this observation, the CD34+ leukemic precursors isolated from a patient with IDH2-mutated AML at baseline and during enasidenib treatment showed progressive and marked improvements in their fitness over time, in terms of CFU ability and propensity to differentiate. They attained clonal trilinear reconstitution of hematopoiesis and complete hematological remission.

22 June 2024 in American Journal of Hematology
Verified
Journal Article
Open access
AVAlessandra Venanzi
Alessandra Venanzi
VCValeria Cardinali
Valeria Cardinali
VPVincenzo Maria Perriello
Vincenzo Maria Perriello
Francesco AlbanoFrancesco Albano
Francesco Albano
GCGaetano Cimino
Gaetano Cimino
‪‪‪Brunangelo ‪Falini
‪Brunangelo ‪Falini

8 July 2025 in Annals of Hematology
Verified
Journal Article
Open access
PDF file
GCGaetano Cimino
Gaetano Cimino
MCMatteo Caridi
Matteo Caridi
VCValeria Cardinali
Valeria Cardinali
SSSofia Sciabolacci
Sofia Sciabolacci
SSSara De Santis
Sara De Santis
MMMaria Paola Martelli
Maria Paola Martelli
Despite the greater biological understanding and the new drugs available, acute myeloid leukaemia (AML) patients who are refractory to intensive induction chemotherapy represents an unmet clinical need, especially in young/fit adults who are eligible for bone marrow transplantation. Since venetoclax/azacitidine (ven/aza) was introduced in AML management in 2020, survival of elderly/unfit patients has dramatically improved, especially in those carrying NPM1 or IDH2 mutations. However, the use of ven/aza in young and fit adults remains limited, raising ongoing debate about its potential role beyond patients ineligible to intensive chemotherapy. Here, we discuss three under 60 years chemorefractory AML patients, who, given the concomitant IDH2 mutations, were started to ven/aza as bridge-to-transplant and successfully treated. These cases confirm the extraordinary sensitivity of IDH2-mutated AML to aza/ven even in the refractoriness setting and show that such less-intensive regimen can be driven by genetics offering a promising alternative to intensive salvage chemotherapy, while preserving patient fitness for allo-transplant.

22 November 2025 in American Journal of Hematology
Verified
Journal Article
Open access
MMMatteo Molica
Matteo Molica
GMGema Miralles
Gema Miralles
RDRichard Dillon
Richard Dillon
MAMario Annunziata
Mario Annunziata
FBFaisal Basheer
Faisal Basheer
Salvatore PerroneSalvatore Perrone
Salvatore Perrone
Gilteritinib is a selective FLT3 inhibitor approved for the treatment of relapsed or refractory (R/R) FLT3 ‐mutated acute myeloid leukemia (AML) following ≥ 1 prior line of therapy. However, data on its effectiveness in later‐line settings is limited. We conducted a multicenter, retrospective study including 171 adult patients with R/R FLT3 ‐mutated AML who received gilteritinib as third‐line or beyond between August 2017 and March 2024 across centers in Italy, Spain, the United Kingdom, and Turkey. The primary endpoint was overall survival (OS). Secondary endpoints included overall response rate (ORR), composite complete remission (cCR), duration of response. Among the 171 patients, 84% carried FLT3 ‐ITD mutations and 26% had received ≥ 3 prior lines of therapy. The cCR rate was 28%, and ORR was 47%. Patients who were younger and presented with relapsed (vs. refractory) disease had better outcomes. Prior exposure to venetoclax or allogeneic hematopoietic stem cell transplantation (HSCT) was associated with inferior response. Gilteritinib enabled HSCT in 12% of patients. Median OS was 7.1 months (95% CI, 5.9–10.1), and in Cox‐regression analysis was significantly improved among responders and those who underwent HSCT (median OS: 21.5 months; 95% CI, 12.8–NR). Prior venetoclax exposure was associated with shorter survival (5.7 months; 95% CI, 5.1–8.8). On multivariate analysis, previous exposure to venetoclax and FLT3 inhibitors was the strongest predictor of reduced response rates. Despite heavy pretreatment, gilteritinib retained clinically relevant activity in later‐line R/R FLT3 ‐mutated AML. Its use beyond second‐line may serve as a bridge to HSCT in selected patients. Resistance mechanisms, particularly following venetoclax, remain a therapeutic challenge. These data support the continued use of gilteritinib beyond second‐line and highlight the need for prospective studies to optimize sequencing strategies.

25 June 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
SPSara Pierangeli
Sara Pierangeli
SDSerena Donnini
Serena Donnini
VCValerio Ciaurro
Valerio Ciaurro
FMFrancesca Milano
Francesca Milano
VCValeria Cardinali
Valeria Cardinali
MMMaria Paola Martelli
Maria Paola Martelli
How hematopoietic stem and progenitor cell (HSPC) fate decisions are affected by genetic alterations acquired during AML leukemogenesis is poorly understood and mainly explored in animal models. Here, we studied isocitrate dehydrogenases (IDH) genes mutations in the human model of HSPC and provide a review of the literature on this topic. IDH1/2 mutations occur in ~20% of AML, are recognized among the mutations earliest acquired during leukemogenesis, and are target of specific inhibitors (ivosidenib and enasidenib, respectively). In order to investigate the direct effects of these mutations on the HSPC we expressed by lentiviral transduction either IDH1-R132H or IDH2-R140Q mutants into human CD34+ healthy donor cells and analyzed the colony-forming unit (CFU) ability. CFU ability was dramatically compromised with a complete trilineage block of differentiation. Strikingly, the block was reversed by the specific inhibitors, confirming it was a specific effect induced by the mutants. In line with this observation, the CD34+ leukemic precursors isolated from a patient with IDH2-mutated AML at baseline and during enasidenib treatment showed over time a progressive and marked improvement of their fitness in terms of CFU ability and propensity to differentiate, attaining clonal trilinear reconstitution of hematopoiesis and complete hematological remission.

22 July 2023 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
GMGiovanni Martino
Giovanni Martino
GCGaetano Cimino
Gaetano Cimino
MCMatteo Caridi
Matteo Caridi
GPGiuseppe Perta
Giuseppe Perta
VCValeria Cardinali
Valeria Cardinali
MMMaria Paola Martelli
Maria Paola Martelli